Ratutrelvir, a ritonavir-free Main protease (Mpro/3CL) inhibitor, was discovered and developed ab initio from target to clinic by ChemDiv's medicinal chemistry and virology services teams. Leveraging ...
The publication reports the highly selective, DCAF16 E3 enabled degradation of BRD9 in vivo using Amphista’s proprietary, next generation ...
News Medical on MSN
Research Reveals New Method to Target Cell Receptors
New research led by the University of Minnesota Medical School demonstrates that molecules acting as "molecular bumpers" and ...
News-Medical.Net on MSN
Novel approaches to understanding EETs and cardiovascular disease
Some products of arachidonic acid have already been well studied: the prostanoids formed by cyclooxygenases are central ...
Some products of arachidonic acid have already been well studied: the prostanoids formed by cyclooxygenases are central mediators of inflammation ...
< Epoxyisotrienic acids (EETs) are rapidly incorporated into lipids of varying complexity, which could ...
Germany sold more than 15 million tonnes of pharmaceutical products to China in 2024, while China sold more than 33 million tonnes to Germany.View on euronews ...
Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today ...
The research is supported by the National Institute of Allergy and Infectious Diseases of the NIH under award number ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback